Alzamend Neuro Granted Extension By Nasdaq Panel To Regain Compliance With The Minimum Bid Price Continued Listing Requirement
Portfolio Pulse from Benzinga Newsdesk
Alzamend Neuro has been granted an extension by the Nasdaq panel to regain compliance with the minimum bid price continued listing requirement.
September 22, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Alzamend Neuro has been granted an extension by Nasdaq to regain compliance with the minimum bid price requirement. This could potentially stabilize the company's stock price in the short term.
The extension granted by Nasdaq allows Alzamend Neuro more time to regain compliance with the minimum bid price requirement. This could potentially prevent the company's stock from being delisted, which would likely have a negative impact on the stock price. Therefore, this news could stabilize the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100